ICON Public Limited Company Share Price

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 23/07/2024 am IST 5-day change 1st Jan Change
339.9 USD +3.10% Intraday chart for ICON Public Limited Company -0.27% +20.09%
Sales 2024 * 864.35Cr 72TCr Sales 2025 * 930.91Cr 78TCr Capitalization 2.73TCr 2,28000Cr
Net income 2024 * 81Cr 6.77TCr Net income 2025 * 98Cr 8.15TCr EV / Sales 2024 * 3.41 x
Net Debt 2024 * 218.01Cr 18TCr Net Debt 2025 * 94Cr 7.9TCr EV / Sales 2025 * 3.03 x
P/E ratio 2024 *
33 x
P/E ratio 2025 *
26.9 x
Employees 41,150
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.35%
More Fundamentals * Estimated data
Dynamic Chart
1 day+3.10%
1 week-0.27%
Current month+8.44%
1 month+6.63%
3 months+14.10%
6 months+28.16%
Current year+20.09%
More quotes
1 week
324.78
Extreme 324.78
345.86
1 month
311.06
Extreme 311.06
347.72
Current year
244.59
Extreme 244.59
347.72
1 year
221.20
Extreme 221.195
347.72
3 years
171.43
Extreme 171.43
347.72
5 years
104.28
Extreme 104.275
347.72
10 years
46.75
Extreme 46.75
347.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 01/11/01
Director of Finance/CFO 45 01/06/01
Chairman 61 03/05/03
Members of the board TitleAgeSince
Founder 71 01/90/01
Chief Executive Officer 63 01/11/01
Director/Board Member 68 01/21/01
More insiders
Date Price Change Volume
22/24/22 339.9 +3.10% 425,585
19/24/19 329.7 +0.58% 371,607
18/24/18 327.8 -1.83% 530,994
17/24/17 333.9 -3.55% 685,444
16/24/16 346.2 +1.57% 699,825

Delayed Quote Nasdaq, July 23, 2024 at 01:30 am IST

More quotes
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
329.7 USD
Average target price
364.2 USD
Spread / Average Target
+10.46%
Consensus